Protagenic Therapeutics Cash Flow-to-Debt Ratio
Protagenic Therapeutics cash flow-to-debt ratio. Protagenic Therapeutics (PTIX) has a Cash Flow-to-Debt Ratio of -0.06x as of December 2025, meaning its operating cash flow of $-410.42K could theoretically repay 0% of its total liabilities ($6.82 Million) in one year. Check earnings quality score of Protagenic Therapeutics to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Protagenic Therapeutics (1995–2025)
Cash flow-to-debt ratio of Protagenic Therapeutics from 1995 to 2025. Historical debt coverage capacity for Protagenic Therapeutics across 31 annual periods. Check Protagenic Therapeutics (PTIX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Protagenic Therapeutics Cash Flow-to-Debt Ratio by Year (1995–2025)
Protagenic Therapeutics cash flow-to-debt ratio by year from 1995 to 2025. Year-by-year debt coverage analysis for Protagenic Therapeutics. For the full cash flow conversion analysis, see Protagenic Therapeutics cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.61x | $-4.14 Million | $6.82 Million | ▲ +86.4% |
| 2024 | -4.47x | $-4.22 Million | $942.76K | ▲ +20.9% |
| 2023 | -5.65x | $-3.70 Million | $655.25K | ▼ -217.5% |
| 2022 | -1.78x | $-1.99 Million | $1.12 Million | ▲ +28.9% |
| 2021 | -2.50x | $-2.80 Million | $1.12 Million | ▼ -276.6% |
| 2020 | -0.66x | $-1.35 Million | $2.03 Million | ▼ -101.2% |
| 2019 | -0.33x | $-487.99K | $1.48 Million | ▲ +72.0% |
| 2018 | -1.18x | $-1.07 Million | $907.77K | ▲ +52.0% |
| 2017 | -2.46x | $-1.38 Million | $561.69K | ▼ -47.6% |
| 2016 | -1.67x | $-1.14 Million | $684.86K | ▼ -210.1% |
| 2015 | -0.54x | $-378.00K | $704.00K | ▲ +10.5% |
| 2015 | -0.60x | $-378.00K | $630.00K | ▲ +76.0% |
| 2014 | -2.50x | $-790.00K | $316.00K | ▲ +0.0% |
| 2013 | -2.50x | $-790.00K | $316.00K | ▼ -13927.8% |
| 2012 | -0.02x | $-324.00K | $18.18 Million | ▲ +98.2% |
| 2010 | -1.01x | $-11.25 Million | $11.17 Million | ▼ -543.1% |
| 2009 | -0.16x | $-3.02 Million | $19.25 Million | ▼ -186.7% |
| 2008 | 0.18x | $4.36 Million | $24.11 Million | ▲ +124.6% |
| 2007 | -0.73x | $-5.21 Million | $7.10 Million | ▼ -436.7% |
| 2006 | 0.22x | $931.00K | $4.27 Million | ▲ +146.8% |
| 2005 | -0.47x | $-44.00K | $94.47K | ▼ -133.2% |
| 2004 | -0.20x | $-842.00K | $4.21 Million | ▼ -193.6% |
| 2003 | 0.21x | $1.87 Million | $8.76 Million | ▼ -21.2% |
| 2002 | 0.27x | $2.35 Million | $8.65 Million | ▲ +74.9% |
| 2001 | 0.15x | $1.50 Million | $9.71 Million | ▼ -60.0% |
| 2000 | 0.39x | $3.51 Million | $9.06 Million | ▲ +1029.6% |
| 1999 | 0.03x | $331.00K | $9.66 Million | ▲ +159.5% |
| 1998 | -0.06x | $-434.00K | $7.53 Million | ▲ +93.5% |
| 1997 | -0.89x | $-2.20 Million | $2.47 Million | ▼ -2042.5% |
| 1996 | -0.04x | $-230.00K | $5.53 Million | ▲ +75.3% |
| 1995 | -0.17x | $-600.00K | $3.57 Million | — |